NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $5.25 -0.16 (-2.96%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$5.01▼$5.4250-Day Range$2.30▼$5.5052-Week Range$1.90▼$8.48Volume36,968 shsAverage Volume672,241 shsMarket Capitalization$70.35 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CASI Pharmaceuticals alerts: Email Address CASI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside14.3% Upside$6.00 Price TargetShort InterestHealthy0.94% of Float Sold ShortDividend StrengthN/ASustainability-1.50Upright™ Environmental ScoreNews Sentiment1.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.56) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.99 out of 5 starsMedical Sector185th out of 896 stocksPharmaceutical Preparations Industry73rd out of 424 stocks 2.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CASI Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.94% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 23.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CASI Pharmaceuticals is -1.50. Previous Next 2.9 News and Social Media Coverage News SentimentCASI Pharmaceuticals has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CASI Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.23% of the stock of CASI Pharmaceuticals is held by institutions.Read more about CASI Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($2.56) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CASI Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsMassive July 4th Discount InsideTo celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.Claim your exclusive offer here>>> About CASI Pharmaceuticals Stock (NASDAQ:CASI)CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Read More CASI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CASI Stock News HeadlinesJuly 2 at 1:52 AM | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.comJune 26, 2024 | prnewswire.comCASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the CompanyJuly 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?June 26, 2024 | prnewswire.comCASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HeMay 26, 2024 | finance.yahoo.comCASI Pharmaceuticals, Inc. (CASI)May 15, 2024 | prnewswire.comCASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)May 14, 2024 | finanznachrichten.deCASI Pharmaceuticals, Inc.: Casi Pharmaceuticals Announces First Quarter 2024 Business And Financial ResultsMay 14, 2024 | investorplace.comCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024July 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?May 14, 2024 | prnewswire.comCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSApril 24, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)April 24, 2024 | finance.yahoo.comBioInvent International AB: Interim Report January-March 2024April 10, 2024 | investing.comCASI Pharmaceuticals updates on Juventas disputeApril 8, 2024 | finance.yahoo.comCASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASMarch 28, 2024 | benzinga.comRecap: CASI Pharmaceuticals Q4 EarningsMarch 28, 2024 | markets.businessinsider.comCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSMarch 18, 2024 | finanznachrichten.deAptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe ConferenceMarch 16, 2024 | finance.yahoo.comCASI Apr 2024 2.500 callMarch 11, 2024 | markets.businessinsider.comPsyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic DivisionMarch 8, 2024 | msn.comAptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare moversMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 10.000 callMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 7.500 putMarch 5, 2024 | msn.comCASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese PatientsMarch 5, 2024 | msn.comCASI stock rises on positive interim data from early stage trial for its NHL treatment in ChinaMarch 5, 2024 | marketwatch.comCASI Pharma Shares Soar After Positive Preliminary Trial Data for Cancer ImmunotherapyMarch 5, 2024 | prnewswire.comCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaSee More Headlines Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/04/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CASI CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees176Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+14.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,940,000.00 Net Margins-105.76% Pretax Margin-106.79% Return on Equity-110.11% Return on Assets-38.84% Debt Debt-to-Equity Ratio1.20 Current Ratio5.05 Quick Ratio3.25 Sales & Book Value Annual Sales$33.88 million Price / Sales2.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.81 per share Price / Book2.90Miscellaneous Outstanding Shares13,400,000Free Float10,555,000Market Cap$70.35 million OptionableOptionable Beta0.68 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Wei-Wu He Ph.D. (Age 59)Chairman & CEO Comp: $565.36kDr. Wei Zhang Ph.D. (Age 64)President Comp: $1.13MDr. Alexander A. Zukiwski M.D. (Age 67)Executive VP & Chief Medical Officer Comp: $514.79kMs. Kun Qian (Age 42)VP & Global Controller Ms. Chunhua Wang (Age 52)Chief Operating Officer Ms. Wei Gao (Age 43)General Counsel Dr. James E. Goldschmidt Ph.D.Chief Business Development OfficerMr. Hai Huang (Age 55)Global Chief Commercial Officer Ms. Amanda CuiVP & Global ControllerMore ExecutivesKey CompetitorsJounce TherapeuticsNASDAQ:JNCEPluristem TherapeuticsNASDAQ:PSTIAmarinNASDAQ:AMRNAlimera SciencesNASDAQ:ALIMADC TherapeuticsNYSE:ADCTView All CompetitorsInstitutional OwnershipHowland Capital Management LLCBought 40,429 shares on 5/4/2024Ownership: 0.302%Wellington Shields Capital Management LLCSold 40,929 shares on 5/3/2024Ownership: 0.688%View All Institutional Transactions CASI Stock Analysis - Frequently Asked Questions Should I buy or sell CASI Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks. What is CASI Pharmaceuticals' stock price target for 2024? 1 analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their CASI share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts. How have CASI shares performed in 2024? CASI Pharmaceuticals' stock was trading at $7.16 at the beginning of the year. Since then, CASI shares have decreased by 26.7% and is now trading at $5.25. View the best growth stocks for 2024 here. Are investors shorting CASI Pharmaceuticals? CASI Pharmaceuticals saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 60,800 shares, a decrease of 23.7% from the May 31st total of 79,700 shares. Based on an average daily volume of 53,800 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.9% of the company's stock are short sold. View CASI Pharmaceuticals' Short Interest. When is CASI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our CASI earnings forecast. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.66. The biotechnology company had revenue of $3.41 million for the quarter. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 110.11% and a negative net margin of 105.76%. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals shares reverse split on the morning of Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM). How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CASI) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredGet in before Reddit doesRobinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.